216 related articles for article (PubMed ID: 38562921)
1. The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma-two sides of the same coin?
Reschke R; Deitert B; Enk AH; Hassel JC
Front Immunol; 2024; 15():1385781. PubMed ID: 38562921
[TBL] [Abstract][Full Text] [Related]
2. Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management.
Plunkett KR; Armitage JD; Inderjeeth AJ; McDonnell AM; Waithman J; Lau PKH
Front Immunol; 2022; 13():1048758. PubMed ID: 36466880
[TBL] [Abstract][Full Text] [Related]
3. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
[TBL] [Abstract][Full Text] [Related]
4. Induction of Progenitor Exhausted Tissue-Resident Memory CD8
León-Letelier RA; Castro-Medina DI; Badillo-Godinez O; Tepale-Segura A; Huanosta-Murillo E; Aguilar-Flores C; De León-Rodríguez SG; Mantilla A; Fuentes-Pananá EM; López-Macías C; Bonifaz LC
Front Immunol; 2020; 11():583382. PubMed ID: 33240271
[TBL] [Abstract][Full Text] [Related]
5. Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy.
Damei I; Trickovic T; Mami-Chouaib F; Corgnac S
Front Immunol; 2023; 14():1205984. PubMed ID: 37545498
[TBL] [Abstract][Full Text] [Related]
6. The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer.
Beumer-Chuwonpad A; Taggenbrock RLRE; Ngo TA; van Gisbergen KPJM
Cells; 2021 Aug; 10(9):. PubMed ID: 34571883
[TBL] [Abstract][Full Text] [Related]
7. Tissue-resident memory T cells in immunotherapy and immune-related adverse events by immune checkpoint inhibitor.
Xiong H; Shen Z
Int J Cancer; 2024 Jul; 155(2):193-202. PubMed ID: 38554117
[TBL] [Abstract][Full Text] [Related]
8. Interferon-Gamma-Producing CD8
Sasson SC; Slevin SM; Cheung VTF; Nassiri I; Olsson-Brown A; Fryer E; Ferreira RC; Trzupek D; Gupta T; Al-Hillawi L; Issaias ML; Easton A; Campo L; FitzPatrick MEB; Adams J; Chitnis M; Protheroe A; Tuthill M; Coupe N; Simmons A; Payne M; Middleton MR; Travis SPL; ; Fairfax BP; Klenerman P; Brain O
Gastroenterology; 2021 Oct; 161(4):1229-1244.e9. PubMed ID: 34147519
[TBL] [Abstract][Full Text] [Related]
9. CD39
Lee YJ; Kim JY; Jeon SH; Nam H; Jung JH; Jeon M; Kim ES; Bae SJ; Ahn J; Yoo TK; Sun WY; Ahn SG; Jeong J; Park SH; Park WC; Kim SI; Shin EC
Sci Immunol; 2022 Aug; 7(74):eabn8390. PubMed ID: 36026440
[TBL] [Abstract][Full Text] [Related]
10. Resident memory T cells, critical components in tumor immunology.
Mami-Chouaib F; Blanc C; Corgnac S; Hans S; Malenica I; Granier C; Tihy I; Tartour E
J Immunother Cancer; 2018 Sep; 6(1):87. PubMed ID: 30180905
[TBL] [Abstract][Full Text] [Related]
11. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
12. Tissue-resident memory T cells in immune-related adverse events: friend or foe?
Reschke R; Gajewski TF
Oncoimmunology; 2023; 12(1):2197358. PubMed ID: 37035636
[TBL] [Abstract][Full Text] [Related]
13. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Han J; Zhao Y; Shirai K; Molodtsov A; Kolling FW; Fisher JL; Zhang P; Yan S; Searles TG; Bader JM; Gui J; Cheng C; Ernstoff MS; Turk MJ; Angeles CV
Nat Cancer; 2021 Mar; 2(3):300-311. PubMed ID: 34179824
[TBL] [Abstract][Full Text] [Related]
14. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
15. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
16. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma.
Chen M; Ma P; Zhang Y; Wang D; Yu Z; Fu Y; Zhao X; Wang M; Zhuang G; Jing Y
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857527
[TBL] [Abstract][Full Text] [Related]
17. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
Grigoriou M; Banos A; Hatzioannou A; Kloetgen A; Kouzis P; Aggouraki D; Zakopoulou R; Bamias G; Kassi E; Mavroudis D; Bamias A; Boumpas DT; Tsirigos A; Gogas H; Alissafi T; Verginis P
Cancer Immunol Res; 2021 Jul; 9(7):726-734. PubMed ID: 33820810
[TBL] [Abstract][Full Text] [Related]
19. Egress of resident memory T cells from tissue with neoadjuvant immunotherapy: Implications for systemic anti-tumor immunity.
Rainey MA; Allen CT; Craveiro M
Oral Oncol; 2023 Nov; 146():106570. PubMed ID: 37738775
[TBL] [Abstract][Full Text] [Related]
20. Elevated circulating memory T cells precede immunotherapy toxicities in melanoma.
Bello E; Dougan M
Trends Cancer; 2022 May; 8(5):347-349. PubMed ID: 35277376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
